Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK 256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor (IC50: 3.2 pM for PDE4B). It can be used for the treatment of chronic obstructive pulmonary disease.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 692 | 5日内发货 | ||
5 mg | ¥ 1,240 | 5日内发货 | ||
25 mg | ¥ 4,280 | 8-10周 | ||
50 mg | ¥ 5,570 | 8-10周 | ||
100 mg | ¥ 8,580 | 8-10周 |
GSK256066 Trifluoroacetate 的其他形式现货产品:
产品描述 | GSK 256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor (IC50: 3.2 pM for PDE4B). It can be used for the treatment of chronic obstructive pulmonary disease. |
靶点活性 | PDE4B:3.2 pM |
体外活性 | GSK 256066 Trifluoroacetate is highly selective for PDE4, with >380,000-fold versus PDE1/2/3/5/6 and >2500-fold against PDE7, and inhibits PDE4 isoforms A-D with equal affinity.?GSK 256066 Trifluoroacetate inhibits tumor necrosis factor α production by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with IC50 of 0.01 nM.GSK 256066 Trifluoroacetate ?is an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration. |
体内活性 | GSK 256066 Trifluoroacetate inhibits LPS-induced pulmonary neutrophilia, and no emetic episodes are observed in ferrets.GSK 256066 Trifluoroacetate (GSK256066 2,2,2-trifluoroacetic acid; 0.3-100 μg/kg; intratracheally) inhibits the eosinophil number increased in the bronchoalveolar lavage (BAL) in a dose-dependent fashion, in lipopolysaccharide (LPS)- and ovalbumin (OVA)-induced acute pulmonary inflammation rat models. |
别名 | GSK 256066 Trifluoroacetate, GSK256066 (2,2,2-trifluoroacetic acid) |
分子量 | 632.61 |
分子式 | C29H27F3N4O7S |
CAS No. | 1415560-64-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (79.04 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5808 mL | 7.9038 mL | 15.8075 mL | 39.5188 mL |
5 mM | 0.3162 mL | 1.5808 mL | 3.1615 mL | 7.9038 mL | |
10 mM | 0.1581 mL | 0.7904 mL | 1.5808 mL | 3.9519 mL | |
20 mM | 0.079 mL | 0.3952 mL | 0.7904 mL | 1.9759 mL | |
50 mM | 0.0316 mL | 0.1581 mL | 0.3162 mL | 0.7904 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK256066 Trifluoroacetate 1415560-64-3 Metabolism PDE GSK256066 GSK 256066 Trifluoroacetate 2,2,2-trifluoroacetic acid GSK-256066 GSK-256066 Trifluoroacetate GSK256066 (2,2,2-trifluoroacetic acid) GSK 256066 Inhibitor inhibitor inhibit